Pharmacotherapy of Zollinger-Ellison syndrome.
Pharmacotherapy of Zollinger-Ellison syndrome.
复制标题
DOI：
10.1517/14656566.2013.767332
复制
发表时间：
2013-02
影响因子：
3.2
通讯作者：
Jensen RT
中科院分区：
文献类型：
--
作者：
Ito T;Igarashi H;Uehara H;Jensen RT
Pharmacotherapy in the management of patients with ZES is often equated with the medical management of the acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is pharmacotherapy in the control of acid hypersecretion; in controlling other hormonal hypersecretory states these patients may develop, including the hyperparathyroidism in patients with MEN1 and ZES; pharmacotherapy involved in tumor localization; and pharmacotherapy involved in the treatment of advanced metastatic disease. The latter includes chemotherapy; liver-directed therapies; biotherapy (somatostatin/interferon); peptide radio-receptor therapy; and molecular targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Pharmacotherapy is now involved in all aspects of management of patients. The result of this is that ZES has progressed from where it initially was entirely a surgical disease to the present where medical treatment plays a major role in almost all aspects of the management of these patients.
登录
查看更多内容
影响因子：
5.9
作者：
BENYA, RV;METZ, DC;JENSEN, RT
通讯作者：
JENSEN, RT
影响因子：
5.8
作者：
Filopanti, Marcello;Verga, Uberta;Spada, Anna
通讯作者：
Spada, Anna
DOI：
10.1038/nrgastro.2012.9
发表时间：
2012-02-07
期刊：
Nature reviews. Gastroenterology & hepatology
影响因子：
--
作者：
通讯作者：
--
影响因子：
39.2
作者：
FISHBEYN, VA;NORTON, JA;JENSEN, RT
通讯作者：
JENSEN, RT
影响因子：
39.2
作者：
COLLEN, MJ;HOWARD, JM;JENSEN, RT
通讯作者：
JENSEN, RT